Long‐term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report

Lei Zhao,Xin Cheng,Hongbin Zhao,Haifei Zhao,Wenyu Di,Zhihong Mei
DOI: https://doi.org/10.3892/ol.2024.14795
2024-11-10
Oncology Letters
Abstract:Neuroendocrine neoplasms of the pancreas (pNENs) are rare. In February 2021, a 54‐year‐old woman was diagnosed with pNEN and multiple metastases within the liver. The patient, diagnosed with grade G2 neuroendocrine neoplasm (T4N0M1), underwent an ultrasonography‐guided liver biopsy and radiofrequency ablation. After receiving Sandostatin LAR in April 2021, side effects led to its discontinuation after seven cycles. Following two sessions of radiofrequency ablation, the patient's condition was stable. However, disease progression was noted in September 2023, resulting in hemodialysis and closed peritoneal drainage. Surufatinib was administered, stabilizing the tumor by November 2023. The patient underwent transarterial chemoembolization due to a large tumor burden, with subsequent MRCP showing stability from diagnosis in February 2021 to June 2024. The present case report highlights the role of tailored treatment strategies considering patient comorbidities and tumor biology, and the significance of secondary puncture biopsy, which, despite not being pursued by the patient in the present study due to the associated risks, may provide survival benefits for patients with advanced or metastatic pNEN.
oncology
What problem does this paper attempt to address?